3D Medicine's First Independently Developed New Drug Approved For Clinical Use

On January 29, 2020, 3D Medicines announced that the clinical trial application of its self-developed category 1 innovative drug 3D011 has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration, marking the approval of 3D Medicines Already have the original research ability to research and develop innovative drugs with global intellectual property rights, which has laid a solid foundation for achieving the company’s long-term sustainable development strategic goals.

3D011 Drug Clinical Trial Approval Notice (Picture source 3D Medicine)

3D011 is a class I innovative drug for the treatment of advanced solid tumors. The parent drug has a good inhibitory effect on related kinases. Clinical data has fully proved its good anti-tumor efficacy. The R&D team of 3D Medicine improved its pharmacokinetic properties through prodrug design, thereby reducing its systemic toxicity, and obtained the innovative drug 3D011.

❖ Medicilon’s Synthetic Chemistry Services

Medicilon can undertake the synthesis of special reagents, intermediates and molecular fragments, preparation of standard products, synthesis design and preparation of impurities or metabolites, synthesis of stable isotope internal standards and synthesis of tritiated compounds.

Aim at chemical synthesis through Ibuprofen

Medicilon FTE services & FFS services - flexible and efficient cooperation model

Medicilon Drug Discovery--Opening the Door of Innovative Drugs with Science and Professionalism

Medicilon was fortunate to cooperate with 3D Medicine in the 3D011 research and development project. Under the guidance of 3D Medicine’s R&D team, Medicilon’s pharmaceutical research team helped 3D Medicine overcome the difficulties in the process of drug synthesis and purification and helped it complete the development of APIs.
Medicilon congratulates the phased success of the 3D011 project, and looks forward to cooperating with 3D Medicine and many innovative drug companies in the future to create a thriving and flourishing innovative drugs, and to watch a new chapter in human health!

About 3D Medicine

3D Medicines Inc. is a biomedical company in the stage of advanced clinical development and early commercialization. Adhering to the concept of “helping cancer patients live longer and better”, it aims at the future trend of slowing cancer treatment , Focusing on developing a new generation of differentiated tumor immunotherapy drugs for cancer patients around the world, extending the survival time of cancer patients and improving the quality of life of patients. The company’s product line includes a new generation of biomacromolecule drugs and small molecule chemical drugs, and has a team with international new drug development, registration and commercial operation capabilities.

About Medicilon

Medicilon (stock code: 688202) was established in 2004 and is headquartered in Shanghai. It is committed to providing a full range of preclinical new drug research services for global pharmaceutical companies, research institutions and scientific researchers. Medicilon’s one-stop integrated service helps customers accelerate the development of new drugs with strong project management and more efficient and cost-effective R&D services. The services cover the entire process of preclinical new drug research in medicine, including drug discovery, pharmaceutical research and clinical trials, pre-research. Medicilon grows together with high-quality customers at home and abroad, and provides new drug research and development services to more than 700 customers around the world. Medicilon will continue to base itself on a global perspective, gather Chinese innovation, and contribute to human health!

In Vitro Enzyme Activity Assay

Kinases play extensive and important roles in signal transduction and co-ordination of complex functions. Currently, about 300 kinase inhibitors have been approved for marketing, among which receptor tyrosine kinase (RTK) inhibitors are the main ones. Medicilon provides high-quality kinase profile screening and has one-stop kinase research services from assay development, high-throughput screening to selectivity analysis. In addition, Medicilon provides many other enzyme activity screens. Wide Variety Provides 200+ in vitro enzymatic detection methods; 100+ kinases, including CTK, RTK, AGC, CMGC and other kinase families as well as important common mutations Project Flexibility Various types of plates for screening, such as 96 and 384; Multiple flexible kinase profiles, including TK kinase family, CDK kinase family, etc., to meet different customer customization needs. Various Methods Fluorescence detection; Chemiluminescence detection; Absorbance detection LanthaScr...

阅读全文

Custom Synthesis

Medicilon has synthesized over 10,000 individual compounds from gram to kilogram quantities, and many compounds are synthesized with more than ten synthetic steps. The overall synthesis success rate is over 95%. High quality products from mg to kg scale Reagents, intermediates, building blocks, and scaffolds Preparation of API or reference standards Development of synthetic routes for impurities and metabolites On-site analytical support Product delivered with COA Medicilon offers integrated drug discovery services -- Chemistry, Biology & Preclinical Services

阅读全文

Fluorescence Probes Synthesis

Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. Design and synthesis steps Fluorescent probes are tools used to detect, measure and analyze biomolecules, cells and tissues. They achieve these purposes by emitting and receiving fluorescent signals. Medicilon can complete the design and synthesis of fluorescent probes for biomolecules. Selection of target molecules and determination of target. Selection of fluorescent dyes. Design of molecular structure. Synthesize probe molecules. Testing the properties of probe molecules. Custom synthesis Medicilon's fluorescent probes and labeling platforms can provide fluorescent probe design and synthesis services for scientific institutions, drug R&D companies, and other customers. After years of development, Medicilon's fluorescent probes and labeling platforms have accumulated rich experience...

阅读全文

Shanghai Medicilon Inc.

搜索此博客